Novelix Pharmaceuticals reported a strong FY 2025-26 with revenue rising over 330% to Rs 132.31 crore. Net profit improved significantly to Rs 2.56 crore, up from Rs 0.08 crore in the previous year. The company confirmed an unmodified auditor opinion and announced the proposed appointment of a new Whole-time Director. No dividend was declared as the company prioritizes reinvesting surplus into working capital for its pharmaceutical intermediate and research operations.
Novelix Pharmaceuticals Reports Major Growth in FY 2025-26
Revenue: Rs 132.31 crore; Profit After Tax: Rs 2.56 crore.
Reader Takeaway: Strong revenue scaling and profitability improvement, though investors should monitor R&D execution and audit trail technical fixes.
What just happened
Novelix Pharmaceuticals has released its FY 2025-26 annual results, showing massive year-on-year growth. Revenue climbed to Rs 132.31 crore from Rs 30.72 crore. Net Profit After Tax rose to Rs 2.56 crore, reflecting a substantial transition in operational performance. The company successfully maintained an unmodified opinion from statutory auditors.
Why this matters
The jump in Return on Equity (ROE) from 0.68% to 7.99% indicates the company is utilizing capital more efficiently as it scales its bulk drug and life science research business. This transition suggests the firm is moving past its early-stage consolidation phase.
Board and Governance
The board has proposed Mr. Gnana Prakash Gattu as a Whole-time Director for a five-year term, pending shareholder approval at the AGM on September 30, 2026. Ms. Sridevi Belide is set for re-appointment after rotating off the board. Management has also confirmed that internal financial controls remain effective.
Risks to watch
The company reported minor technical hurdles in its audit trail (edit log) software, which are currently being rectified with the vendor. Additionally, as a player in the pharmaceutical sector, the company remains exposed to regulatory, technological, and market-related risks inherent in the industry.
What to track next
Investors should look for updates on the integration of the audit trail system and the company's ability to maintain its margin expansion as it pushes further into the competitive pharmaceutical intermediates and healthcare research markets.